Fresenius Kabi Launches Generic Avelox Injection

Fresenius Kabi Launches Generic Avelox Injection
Fresenius Kabi Launches Generic Avelox Injection

Fresenius Kabi announced the launch of Moxifloxacin Injection in the company's Freeflex delivery system, the first generic version of Bayer's Avelox Injection.

Moxifloxacin Injection is a quinolone antibiotic indicated for the treatment of adults ≥18 years of age with infections caused by susceptible isolates of the designated microorganisms in acute bacterial sinusitis; acute bacterial exacerbation of chronic bronchitis; community acquired pneumonia; uncomplicated skin and skin structure infections; complicated skin and skin structure infections; and complicated intra-abdominal infections. Freeflex is a non-PVC and non-DEHP flexible bag for infusion solutions using patented port technology and clear labeling.

RELATED: Avelox Approved for Plague Prevention, Treatment

Moxifloxacin Injection is available as a 400mg/250mL strength in 300mL bags in a single-use, ready-to-use Freeflex container.

For more information call (888) 386-1300 or visit Fresenius-Kabi.us.

Loading links....